Coronavirus: Oxford's vaccine trial has 50 percent chance of success

Published: Updated:

The University of Oxford's COVID-19 vaccine trial has only a 50 percent chance of success as the coronavirus seems to be fading rapidly in Britain, the professor co-leading the development of the vaccine told the Telegraph newspaper.

Adrian Hill, director of Oxford's Jenner Institute, which has teamed up with drug maker AstraZeneca to develop the vaccine, said that an upcoming trial, involving 10,000 volunteers, threatened to return “no result” due to low transmission of COVID-19 in the community.

For all the latest coronavirus news visit our dedicated page.

“It's a race against the virus disappearing, and against time”, Hill told the British newspaper. “At the moment, there’s a 50 percent chance that we get no result at all.”

The experimental vaccine, known as ChAdOx1 nCoV-19, is one of the front-runners in the global race to provide protection against the new coronavirus causing the COVID-19 pandemic.

Hill's team began early-stage human trials of the vaccine in April, making it one of only a handful to have reached that milestone.

Read more:

COVID-19: 80 million children at risk of vaccine-prevented diseases, says WHO, UNICEF

UK drugmaker AstraZeneca gets $1 bln in US funding to make Oxford coronavirus vaccine

Coronavirus vaccine: Monkeys infected with COVID-19 develop immunity in studies